

Infection Control in Home Care, Volume Two

- Section 1- **Human Immunodeficiency Virus (HIV)**
- Section 2- **Influenza**
- Section 3- **Hepatitis**
- Section 4- **Health Care Worker Restrictions**
- Section 5- **Rabies**
- Section 6- **Nosocomial Infections**
- Section 7- **Latex Allergies**
- Section 8- **Infectious Disease Updates for Educational Seminars**
- Section 9- **Federal Register- Bloodborne Pathogens**
- Section 10- **Glossary**

Table of Contents

Section 1- Human Immunodeficiency Virus (HIV)

Introduction:	1-1
HIV Exposure	1-2
Determining the Need for HIV Postexposure (PEP) after an Occupational Exposure	1-3
Staff Education Concerning Occupational Exposures to HIV	1-6
Human Bites	1-8
Follow-up Counseling and Medical Evaluation of Post-Exposed Health Care Workers	1-9
PEP Regimens	1-11
PEP Following Occupational Exposure	1-12
Occupational Exposure to HIV: Comparison of NYSDOH and CDC Recommendations	1-13
Use of Monitoring Checklist	1-15
Evaluation and Testing of Exposure Source	1-17
Antiretroviral Drug Therapy In Pediatric HIV Infection	1-18
Recommended antiretroviral regimens for Initial Therapy for HIV Infection in Children	1-19
1994 Revised HIV Pediatric Classification System	1-20
Antiretroviral Drug Use in Pregnant Women	1-22
Antiretroviral Use in HIV Infected Adults and Adolescents	1-25
Rate of Decline of Plasma HIV RNA Concentration after Initiation of Potent Combination Antiretroviral Therapy	1-27
Likelihood of Developing AIDS within 3 years	1-28
Indications for Plasma HIV RNA Testing	1-29
Indications for the Initiation of Antiretroviral Therapy in the Chronically HIV-Infected Patient	1-30
Care of Occupationally Exposed Site	1-31
HIV Counseling and Education after an Occupational Exposure	1-32
Employee Occupational Exposure Documentation (Forms)	1-42
AIDS Information	1-44

Section 2- Influenza

Prevention and Control of Influenza	2-1
---	-----

Antiviral Agents for Influenza A	2-11
Influenza Vaccine (Patient Handout)	2-16
Vaccine Administration Record	2-19
Influenza-Like Illness Log for Home Care Agencies (Handout)	2-20

Section 3- Hepatitis

Hepatitis A	3-1
Hepatitis B	3-5
Updated Recommendations for Hepatitis C Virus Infection	3-9
Viral Hepatitis Transmissions Routes (Handout)	3-14

Section 4- Health Care Worker Restrictions

Subject: Pregnant Health Care Worker Restriction	4-1
Subject: Health Care Worker Restriction	4-2
Subject: Work Restriction and Employee Education	4-3
For Specific HIV Exposure & Treatment, See Part II, Section I	4-4
Suggested Intervals Between Administration of Immune Globulin Preparations For Various Indications and Vaccines Containing Live-Measles Virus	4-5
Work Restrictions For Health-Care Workers (HCWs) Exposed To or Infected With Certain Vaccine-Preventable Diseases	4-6
Summary of ACIP Recommendations Concerning Immunization of Health- Care Workers with Special Conditions (Handout)	4-8
Table 2. Immunizing Agents and Immunization Schedules for Health Care Workers (HCWs)*	4-9

Section 5- Rabies

Rabies	5-1
Rabies Postexposure Prophylaxis Schedule- United States, 1999	5-6
Rabies Postexposure Prophylaxis Guide- United States, 1999	5-7

Section 6- Nosocomial Infections

Nosocomial Infections	6-1
CDC Definitions of Nosocomial Infections (Handouts)	
National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from October 1986-April 1998, Issued June 1998 (Handouts)	

Section 7- Latex Allergies

Subject: Latex Exposures and/or Allergy	7-1
NIOSH Recommendations For Latex Allergies In Health Care Workers	7-3
Subject: Equipment Containing Natural Latex Rubber	7-12
Subject: Latex Allergy Questionnaire	7-13

Section 8- Infectious Disease Updates For Educational Seminars

Chain of Infection	8-1
Babesiosis	8-2
Cat Scratch Disease	8-5
Chlamydial Infections	8-6
Number and Rate of Reported Cases of Chlamydia trachomatis Infection, By State and Sex- United States, 1995 (Chart)	8-8
Percentage of Chlamydia Test Positivity Among Women	8-9
Coccidioidomycosis	8-10
Clinical Presentation of Coccidioidomycosis in AIDS	8-12
Side Effects of Drugs Used in Treatment of Coccidioidomycosis	8-13
Mean Annual Incidence Rate of Coccidioidomycosis, By Age Group- Arizona, 1990-1995	8-14
Creutzfeldt-Jakob Disease	8-15
Number of Deaths from Creutzfeldt-Jakob Disease, By Year and Age group, and Average Annual Death Rate By Age Group- Active Surveillance Sites, 1991-1995	8-17
Cryptosporidiosis	8-18
Cyclospora	8-20
Cytomegalovirus (CMV)	8-22
Ebola	8-28
Dengue Fever	8-30
Suspected and Laboratory-Diagnosed Cases of Imported Dengue, By State- United States 1995	8-33
Epstein-Barr Virus	8-34
Hantavirus	8-39
Lyme Disease	8-41
Number of Reported Lyme Disease Cases, By State- United States 1994	8-44
Lyme Disease Update	8-45
Malaria	8-46
Ringworm	8-48
Q Fever	8-50

Scabies 8-52
Tuberculosis 8-54
Tularemia 8-55
Typhoid..... 8-57

Section 9- Federal Register- Bloodborne Pathogens

Occupational Exposure To Bloodborne Pathogens (Handouts)

Section 10- Glossary

Glossary

Subject: Determining the Need for HIV Postexposure (PEP) after an Occupational Exposure


Policy: Occupational exposure PEP treatment will be based on the 3 steps, as recommended by the Centers for Disease Control (New York State protocols will be followed by those agencies in New York or those agencies in other states who wish to follow New York State protocols). See: New York State protocols.

Practice/Procedure/Implementation:

1. The agency will determine the exposure code (EC). See flow chart following this policy.
2. The agency will determine the HIV status code (HIV SC). See flow chart following this policy.
3. Agency will recommend the PEP as indicated by the results of both the exposure code and the HIV status code. See recommendation chart following this policy.

Determining the need for HIV postexposure prophylaxis (PEP) after an occupational exposure*

STEP 1: Determine the Exposure Code (EC)



* This algorithm is intended to guide initial decisions about PEP and should be used in conjunction with other guidance provided in this report.

† Semen or vaginal secretions; cerebrospinal, synovial, pleural, peritoneal, pericardial, or amniotic fluids; or tissue.

§ Exposures to OPIM must be evaluated on a case-by-case basis. In general, these body substances are considered a low risk for transmission in health-care settings. Any unprotected contact to concentrated HIV in a research laboratory, or production facility is considered an occupational exposure that requires clinical evaluation to determine the need for PEP.

¶ Skin integrity is considered compromised if there is evidence of chapped skin, dermatitis, abrasion, or open wound.

** Contact with intact skin is not normally considered a risk for HIV transmission. However, if the exposure was to blood, and the circumstance suggests a higher volume exposure (e.g., an extensive area of skin was exposed or there was prolonged contact with blood), the risk for HIV transmission should be considered.

†† The combination of these severity factors (e.g., large-bore hollow needle and deep puncture) contribute to an elevated risk for transmission if the source person is HIV-positive.